Objectives: Antipsychotics are routinely administered to patients with traumatic brain injury, even though the benefits vs. risks of this approach on behavioral recovery are unclear. To clarify the issue, the present study evaluated the effect of single and multiple administrations of haloperidol and risperidone on functional outcome after traumatic brain injury.
T raumatic brain injury (TBI) induces a plethora of secondary sequelae, which include, but are not limited to, alterations in neurotransmitter systems (1) (2) (3) (4) (5) and neurobehavioral dysfunction (6 -11) .
Regarding the former, regional increases in dopamine levels have been detected as early as 5 mins to 1 hr after accelerationdeceleration brain injury (3) . Cortical dopamine levels have been reported to decrease by 1 hr after fluid percussioninduced brain injury and remain depressed for up to 2 wks (5) . Dopamine tissue levels and metabolism increase acutely, within 1 hr after controlled cortical impact (CCI), and then subsequently normalize during a 2-wk period (4) . Furthermore, both tyrosine hydroxylase, the rate-limiting enzyme in the synthesis of catecholamines, and the dopamine transporter, which plays a critical role in maintaining dopamine homeostasis in the central nervous system, are temporally altered after CCI injury (12) (13) (14) (15) . Moreover, the motor and cognitive deficits produced, in part, by these dopamine alterations are attenuated by treatment with dopamine D2 receptor agonists in both experimental (9 -11, 16, 17) and clinical (18 -21) studies. Taken together, these data suggest an important role for the dopamine neurotransmitter system in enhancing and maintaining functional recovery after TBI (22) .
In addition to the motor and cognitive deficits, other behavioral manifestations of clinical TBI include agitation and aggression. Managing these symptoms is one of the more frustrating aspects in caring for TBI patients because they may resist treatment, become disruptive, and pose a physical risk to themselves or hospital staff, which ultimately impedes rehabilitation efforts (23) (24) (25) . The administration of antipsychotics is routine for managing TBI-induced agitation, albeit the benefits vs. risks of this approach on behavioral recovery is unclear. Because many of the commonly used antipsychot-ics exert much of their effect by acting as high-affinity dopamine D2 receptor antagonists, this approach may have deleterious consequences after TBI, especially in light of the beneficial actions of D2 receptor agonists. Several experimental studies lend support for this assertion. For example, haloperidol, the prototype for the typical antipsychotics, hinders motor recovery when given singly (2, 26, 27) or chronically (28) after cortical damage. Haloperidol has also been reported to impair cognitive performance when provided chronically after fluid percussion injury (29) . In contrast, neither a single low dose of clozapine nor multiple doses of olanzapine, which have a low affinity for dopamine D2 receptors, have been reported to negatively affect motor and cognitive performance, respectively (27, 29) . Thus, despite several investigative studies, the rehabilitative consequences of administering antipsychotics, particularly those with a high affinity for dopamine D2 receptors, after TBI remain ambiguous. It is likely that the dose, timing, and duration of drug treatment may be compounding the issue. The goal of this study is to help clarify this ambiguity by empirically evaluating the effects of single and multiple administrations of the typical and atypical antipsychotics, haloperidol and risperidone, respectively, on motor and cognitive outcome after experimental TBI.
MATERIALS AND METHODS

Subjects and Surgery.
A total of 60 adult male Sprague-Dawley rats (Harlan, Indianapolis, IN) were housed in standard steel-wire mesh cages and maintained in a temperaturecontrolled (21 Ϯ 1°C) and light-controlled (on 7:00 am to 7:00 pm) environment with food and water available ad libitum. After 1 wk of acclimatization, the rats (300 -325 g) were randomly assigned to either CCI or shaminjury groups. In addition to the contusion, CCI injury produces many other morphologic and cerebrovascular responses that are seen after human TBI, such as subarachnoid hemorrhage, hematoma, hippocampal cell loss, axonal injury, edema, altered cerebral blood flow and metabolism, and ischemia. CCI injury also produces neurobehavioral deficits (e.g., motor skills such as locomotion) and cognitive impairments (spatial learning, retention, and working memory) that are reminiscent of those seen clinically (30) . Surgical procedures have been reported in detail elsewhere (8, 10) . Briefly, rats anesthetized with isoflurane (4% in 2:1 N 2 O/O 2 ) were intubated, mechanically ventilated, and then subjected to either a right hemisphere CCI (2.7-mm tissue deformation at 4 m/sec) or craniectomy alone (i.e., sham). Core temperature was maintained at 37 Ϯ 0.5°C during surgery. All experimental procedures were approved by the Animal Care and Use Committee at the University of Pittsburgh and were conducted in accordance with the recommendations provided in the Guide for the Care and Use of Laboratory Animals (Washington, DC, National Academy Press, 1996). Every attempt was made to limit the number of subjects used and to minimize suffering.
Acute Neurologic Evaluation. To assess hind limb reflexive ability, the rats were given brief paw pinches every 10 secs after the cessation of anesthesia and the time to elicit a withdrawal was recorded. To evaluate the return of righting ability, the time required to turn from the supine to prone position on three consecutive trials was recorded.
Motor Training. Beam balance and beam walk tasks were utilized to assess gross and fine motor function, respectively. The beam balance task consists of placing the rat on an elevated (height of 90 cm) narrow wooden beam (width of 1.5 cm) and recording the duration it remains on for a maximum of 60 secs. The beam walk task, originally devised by Feeney et al. (26) , allows for the assessment of locomotion. Briefly, the task consists of training/assessing rats using a negative-reinforcement paradigm to escape ambient light and high-decibel white noise by traversing an elevated (height of 90 cm) narrow wooden beam (2.5 ϫ 100 cm) and entering a darkened goal box at the opposite end. The termination of the aversive stimuli (light and noise) serves as reinforcement (reward). Performance is assessed by the time required to traverse the beam. Rats were tested for both beam balance and beam walk ability on postoperative days 1-5. Three trials (60 secs of allotted time) per day were provided on each task, and the average daily scores for each subject were used in the statistical analyses.
Cognitive Training (Spatial Learning Acquisition and Memory). A Morris water maze task that is sensitive to cognitive function/ dysfunction after TBI (7, 8, 10) was used to compare acquisition rates among groups. The maze consisted of a plastic pool (diameter of 180 cm; height of 60 cm) filled with water (26 Ϯ 1°C) to a depth of 28 cm and was situated in a room with salient visual cues that remained constant throughout the study. The platform consisted of a clear Plexiglas stand (diameter of 10 cm, height of 26 cm) that was positioned 26 cm from the maze wall in the southwest quadrant and held constant throughout the experiment. Spatial learning acquisition and memory began on postoperative day 14 and consisted of providing a block of four daily trials for five consecutive days (days 14 -18) to locate the platform when it was submerged 2 cm below the water surface (i.e., invisible to the rat), followed by an additional day (day 19) to locate the platform when it stood 2 cm above the water surface (visible to the rat). For each daily block of trials, the rats were placed in the pool facing the wall at each of the four possible start locations (north, east, south, and west) in a randomized manner. Each trial lasted until the rat climbed onto the platform or until 120 secs had elapsed, whichever occurred first. Rats that failed to locate the goal within the allotted time were manually guided to it. All rats remained on the platform for 30 secs before being placed in a heated incubator between trials (4-min intertrial interval). The average time of the four trials for each rat were used in the statistical analyses. Swim speed was recorded and assessed with a video analysis system (Chromatrack, San Diego Instruments, San Diego, CA).
Drug Administration. Risperidone (Research Diagnostics, Flanders, NJ) and haloperidol (Sigma, St. Louis, MO) were prepared daily by dissolving in 1:1 dimethyl sulfoxide/ saline vol/vol, which also served as the vehicle. TBI animals were randomly assigned to receive intraperitoneal injections of risperidone (0.045 mg/kg, 0.45 mg/kg, or 4.5 mg/kg; n ϭ 9 in each group), haloperidol (0.5 mg/kg, n ϭ 9), or vehicle (1 mL/kg, n ϭ 9). Sham animals received risperidone (4.5 mg/kg, n ϭ 5), haloperidol (0.5 mg/kg, n ϭ 5), or vehicle (1 mL/kg, n ϭ 5). During phase 1 of the study, all rats received a single intraperitoneal injection 24 hrs after surgery. During phase 2 (postoperative days 19 -23), all groups, which consisted of the same rats from phase 1, received daily injections 1 hr before testing. Treatments were discontinued during phase 3 (i.e., drug washout period), and the rats were reevaluated ( Fig. 1 has an outline of the experimental phases). The 0.45 mg/kg dose of risperidone and the 0.5 mg/kg dose of haloperidol were chosen because these concentrations are equivalent to those used clinically to control psychosis (31) . Risperidone concentrations ten-fold lower and ten-fold higher were also evaluated in an effort to establish a behavioral response profile.
Statistical Analyses. Statistical analyses were performed on data collected by observers blinded to treatment conditions by repeatedmeasures analysis of variance using Statview 4.51 software (Abacus Concepts, Berkeley, CA). When the analysis of variance revealed a significant effect, the Bonferroni post hoc test was utilized to determine specific group differences. The data are expressed as the mean Ϯ SEM and are considered significant when corresponding p values are Յ.05 or as dictated by Bonferroni corrections for multiple comparisons.
RESULTS
Exclusions and Data Pooling. Two rats from the TBI ϩ vehicle group were unsuccessful in locating the visible platform during the allotted 2-min period for each location, which is suggestive of impaired visual acuity, and thus were ex-cluded from the cognitive analyses. Furthermore, post hoc analyses did not reveal significant differences among the sham groups, regardless of treatment in any of the tasks, and thus, the data were pooled and analyzed as one group (designated SHAM).
Acute Neurologic Evaluation. No significant differences were observed among the TBI groups in hind limb reflex with-drawal latency (range, 171.9 Ϯ 3.9 to 188.1 Ϯ 10.4 secs; p Ͼ .05) or return of righting ability (range, 351.2 Ϯ 24.4 to 398.8 Ϯ 24.5 secs; p Ͼ .05). The lack of significant differences with these acute neurologic indices suggests that all TBI groups experienced equivalent injury severities.
Motor Performance (Beam Balance). All groups were able to balance on the beam for the allotted 60 secs on each of three trials before surgery. In contrast, all injured groups displayed significant beam balance impairments on postoperative days 1-3, regardless of treatment. Moreover, all injured groups exhibited a similar rate of spontaneous improvement over time ( Fig. 2A) , and as such, no significant differences were revealed among any of the TBI groups vs. SHAM on postoperative days 4 -5 (all p values were Ͼ.05, Bonferroni). However, during the daily treatment paradigm (second phase of the study), beam balance deficits reoccurred in the TBI ϩ risperidone (4.5 mg/ kg) group. The impairment was different (p Ͻ .05) from the other groups, which did not exhibit a reoccurrence of deficits (Fig. 2B) . Lastly, all groups were reevaluated after a 3-day drug washout period, and although the TBI ϩ risperidone (4.5 mg/kg) group did not return to baseline performance, no statistically significant difference was revealed (Fig. 2C) .
Motor Performance (Beam Walk). Similar to the beam balance results, there were no significant differences in time to traverse the beam among groups before surgery (p Ͼ .05). However, for the first 4 days after TBI, there was a significant increase in beam-walking time for all injured groups vs. SHAM controls. Time to traverse the beam did not The thick black lines refer to the time points (days) corresponding with the three phases of the experiment. Phase 1 included postoperative days 1-18, in which rats received a single administration of one of the treatments (0.045 mg/kg, 0.45 mg/kg, or 4.5 mg/kg risperidone; 0.5 mg/kg haloperidol; or 1 mL/kg vehicle) and tested on the beam on postoperative days 1-5 and in a hidden platform version of the water maze on days 14 -18. Phase 2 consisted of days 19 -23 in which a single visible platform test was provided on day 19, just before commencement of daily treatments (same rats and drug doses as in phase 1) that continued for 5 days. Motor and water maze performance were reevaluated beginning 1 day after the induction of daily treatments. Phase 3 consisted of days 24 -26 and was considered a drug washout period. All rats underwent final behavioral assessments on the beam and water maze on day 26 (3 days after discontinuation of treatments) and were then killed on postoperative day 28. i.p., intraperitoneal injection. Figure 2 . Mean (ϮSEM) balance ability as measured by time (seconds) spent on an elevated wooden beam before and after traumatic brain injury (TBI) or sham injury. During the first phase of the experiment, a single drug injection was provided 1 hr before testing on postoperative day 1 (arrow), which was followed by daily administrations on days 19 -23 during the second phase, and no treatments during the third phase, which consisted of days 24 -26. A, no significant differences were revealed among TBI groups, albeit all were markedly impaired relative to sham controls; B, *p Ͻ .05 vs. all other groups during daily administration; C, assessment at 3 days after the discontinuation of daily treatment revealed no statistically significant differences among groups (p Ͼ .05, Bonferroni post hoc).
differ significantly between the injured groups on any testing day, regardless of treatment (p Ͼ .05), as all groups recovered at the same rate and exhibited near baseline performance by the end of the testing period (Fig. 3A) . During the second phase of the study, both the TBI ϩ risperidone (4.5 mg/kg) and TBI ϩ haloperidol groups exhibited (Fig. 3B ) significant increases in beam walk latencies vs. all other groups (p Ͻ .05). Although the TBI ϩ risperidone (4.5 mg/kg) and TBI ϩ haloperidol groups still seemed to be deficient in beam walk ability after three drug-free days (Fig. 3C) , the post hoc analysis was not significant (p Ͼ .05).
Cognitive Performance (Spatial Learning Acquisition). Analysis of spatial acquisition revealed significant TBI-induced water maze performance deficits. Despite the initial water maze impairment, all injured groups became progressively better at locating the submerged platform over time but were still significantly im-paired relative to the SHAM group, which became quite proficient in performing the task during the testing period (Fig.  4A ). Reevaluation of cognitive performance during the second phase of the study when all groups were receiving daily treatments showed that both the TBI ϩ risperidone (4.5 mg/kg) and TBI ϩ haloperidol groups required significantly more time to locate the platform vs. all other groups (p Ͻ .05), suggesting a reinstatement of deficits (Fig. 4B) . The deficits were still present 3 days after discontinuation of drug treatments (Fig. 4C) 
DISCUSSION
The present study sought to evaluate the effect of typical (haloperidol) and atypical (risperidone) antipsychotics on both motor and cognitive performance after TBI induced by a clinically relevant model (30) . The experiment was conducted in three phases ( Fig. 1) and was designed to determine the effects of a single and early treatment (24 hrs post-TBI or sham surgery), delayed and chronic treatments (18 -23 days post-TBI), and persistence of neurobehavioral effects (after a 3-day drug washout period). The results from the first phase of the study revealed that neither haloperidol nor risperidone, regardless of dose, exerted a deleterious effect on functional outcome, as evidenced by a similar rate of motor recovery and cognitive performance for all antipsychotic-treated groups relative to vehicle-treated controls. In marked contrast, the findings from the second phase showed that daily administration of both haloperidol and the high dose of risperidone (4.5 mg/kg) led to a reoccurrence of beam-walking and water maze impairments. Moreover, as revealed in the third phase, the water maze spatial learning deficits were persistent, as they were still present in the high-dose risperidone-treated group 3 days after discontinuation of treatment.
The lack of significant motor impairment after one treatment is in contrast to that of previously published studies reporting that a single administration of haloperidol 24 hrs after sensorimotor cortex ablation impairs motor recovery for several weeks (2, 26, 27) . The results from the second phase of the study showing a significant deleterious effect of daily administrations of haloperidol on motor function is comparable with a previously published report in which brain trauma was induced via cortical weight drop (28) but not with a study that used fluid percussion (29) . However, water maze performance was impaired in the latter study (29) . The discrepant findings may be at- Figure 3 . Mean (ϮSEM) walking ability as measured by time (seconds) to traverse an elevated wooden beam before and after traumatic brain injury (TBI) or sham injury. During the first phase of the experiment, a single drug injection was provided 1 hr before testing on postoperative day 1 (arrow), which was followed by daily administrations on days 19 -23 during the second phase, and no treatments during the third phase, which consisted of days 24 -26. A, no significant differences were revealed among TBI groups, albeit all were markedly impaired relative to sham controls; B, ϩ*p Ͻ .05 vs. all other groups, but not each other, during daily administration; C, assessment at 3 days after the discontinuation of daily treatment revealed no statistically significant differences among groups (p Ͼ .05, Bonferroni post hoc). tributed to differences in location and size of the lesions and to selective cell loss produced by the different brain injury models (i.e., focal cortical impact vs. cortical ablation and fluid percussion). Another explanation for the differences may stem from inherent characteristics of the motor tasks, such as sensitivity and scoring criteria. For instance, motor performance was evaluated in the current study by recording the overall time required to traverse a beam, which is not as sensitive as evaluating fine motor coordination, such as determining the number of foot slips during beam walking as was done in the studies by Feeney et al. (2, 26) and Goldstein and Bullman (27) .
Because time to traverse the beam or locate the submerged platform was the criterion used for beam-walking and water maze performance, an intuitive explanation for the reoccurrence of deficits is that slower speed, perhaps produced by catalepsy, accounted for the impairments. However, the impaired rats (i.e., high-dose risperidone and haloperidol treated) were generally not slower overall, as demonstrated by traversal times that were similar to the other groups after gentle prodding (that elicits locomotion) and swim speeds that were within the range of vehicle-treated rats. Interestingly, Alleva et al. (32) administered different doses of haloperidol to adult rodents in an effort to determine catalepsy, as measured by latency between paw placement and movement on a wooden bar. They found that the minimal dose to induce complete catalepsy was 10 mg/kg, whereas 0.6 mg/kg, a dose very close to that used in the current study (0.5 mg/kg), had a virtually nonexistent cataleptic response (32) . One neurobehavioral explanation for the reoccurrence of motor and spatial acquisition deficits is that antipsychotic drugs can significantly affect attention, and this can lead to deficit in performance in an already learned task.
Alterations in neural transmission as reported in seminal studies by Feeney et al. (2, 6, 33) and Goldstein and Bullman (27, 34) provide additional explanations for the reinstatement of deficits. Antagonism of dopamine D2 receptors by chronic high-dose treatments of haloperidol and risperidone is a viable choice given the plethora of data that exist showing that the administration of D2 receptor agonists such as amantadine (16) , bromocriptine (9 -10), and methylphenidate (11) improve functional outcome after cortical impact injury in rodents. Furthermore, beneficial effects with these same agents have also been observed in human TBI patients (18 -21) . In addition to D2 receptor antagonism, both haloperidol and risperidone also affect ␣-1 and ␣-2 noradrenergic receptors (35) . An abundance of experimental studies strongly implicate this neurotransmitter system in mediating many of the functional effects (deficits and recovery of function) observed after TBI. Briefly, Feeney and colleagues have shown that drugs with antagonistic effects on noradrenergic receptors, such as haloperidol and clonidine, impede recovery after brain injury and can reinstate clinical deficits long after full recovery has occurred (references 2, 6, 28, 33, 34, 36, 37 provide excellent reviews). Haloperidol and risperidone also have a high affinity for 5-hydroxytryptamine (5-HT) 2A and 5-HT 2C receptors. Serotonergic pathways originating in the raphe nuclei project extensively to brain areas involved in cognitive functions, and serotonin (5-HT) receptor agonists and antagonists alter these processes (38, 39) . Whereas we have studied the effect of 5-HT 1A receptor agonists in learning and memory and have found improved spatial acquisition (8), other groups studying different 5-HT receptors have reported either beneficial or detrimental effects (38, 39) . Taken together, these pharmacologic studies indicate that motor and cognitive function can be affected by manipulating various neurotransmitter systems. Furthermore, because both haloperidol and risperidone affect these systems, it is difficult to ascribe the deleterious effects observed in our study, and in others, to a single neurotransmitter system.
In conclusion, the data indicate that neither a single administration of the antipsychotics haloperidol and risperidone nor multiple low doses impair motor and cognitive function after experimental TBI. However, multiple administrations of haloperidol and high-dose risperidone lead to a reoccurrence of motor and spatial learning deficits. These findings replicate laboratory and clinical data sug- During the first phase of the experiment, a single drug injection was provided 1 hr before testing on postoperative day 1, and thus, rats were not being treated during testing days 14 -18. However, daily administrations were provided during the second phase (postoperative days 19 -23) . No treatments were provided during the third phase (postoperative days 24 -26) . A, no significant differences were revealed among traumatic brain injury (TBI) groups, albeit all are markedly impaired relative to sham controls; B, *ϩp Ͻ .05 vs. all other groups, but not each other, during daily administrations; C, *ϩp Ͻ .05 vs. all other groups, but not each other, 3 days after discontinuation of treatments.
gesting that some commonly prescribed drugs have the ability to produce a reoccurrence of symptoms in fully recovered animals (33) and patients (33, 34) and thus challenges the accepted hypothesis that rewiring underlies recovery. Furthermore, the data indicate that recovery is a fragile state, and physicians should be aware of the possible harmful effects of some drugs on outcome. However, we cannot rule out the possibility that multiple treatments were deleterious because of a confounding influence of previous drug exposure. These findings may have significant relevance for the physician who is faced with the decision of whether to administer antipsychotics to attenuate TBI-induced aggression or agitation so that patient care can resume. However, the implications may be quite different for single use in the critical care setting when compared with chronic use in a rehabilitation environment.
